154 related articles for article (PubMed ID: 33072595)
1. Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer.
Boscolo A; Fortarezza F; Lunardi F; Comacchio G; Urso L; Frega S; Menis J; Bonanno L; Guarneri V; Rea F; Conte P; Calabrese F; Pasello G
Front Oncol; 2020; 10():564915. PubMed ID: 33072595
[TBL] [Abstract][Full Text] [Related]
2. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.
Zou MX; Lv GH; Wang XB; Huang W; Li J; Jiang Y; She XL
Neurosurgery; 2019 Jun; 84(6):E318-E333. PubMed ID: 30032257
[TBL] [Abstract][Full Text] [Related]
4. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.
Kim KJ; Yang HK; Kim WH; Kang GH
Oncotarget; 2017 Aug; 8(35):58887-58902. PubMed ID: 28938605
[TBL] [Abstract][Full Text] [Related]
5. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunoscore approach.
Feng W; Li Y; Shen L; Zhang Q; Cai XW; Zhu ZF; Sun MH; Chen HQ; Fu XL
Ther Adv Med Oncol; 2021; 13():1758835920984975. PubMed ID: 33488784
[TBL] [Abstract][Full Text] [Related]
7. Immunoscore system combining CD8 and PD-1/PD-L1: A novel approach that predicts the clinical outcomes for cervical cancer.
Chen H; Xia B; Zheng T; Lou G
Int J Biol Markers; 2020 Mar; 35(1):65-73. PubMed ID: 31808707
[TBL] [Abstract][Full Text] [Related]
8. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8
Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G
Front Immunol; 2021; 12():680973. PubMed ID: 34122444
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy.
Chen J; Zhong W; Yang M; Hou W; Wang X; Xia K; Yu H; Yang M; Zhou B; Wang B; Huang J; Lin T
Cancer Immunol Immunother; 2021 Sep; 70(9):2657-2668. PubMed ID: 33606065
[TBL] [Abstract][Full Text] [Related]
10. Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients.
Yang Y; Yang X; Wang Y; Xu J; Shen H; Gou H; Qin X; Jiang G
Front Immunol; 2022; 13():811007. PubMed ID: 35222387
[TBL] [Abstract][Full Text] [Related]
11. A new method for predicting survival in stage I non-small cell lung cancer patients: nomogram based on macrophage immunoscore, TNM stage and lymphocyte-to-monocyte ratio.
Gao J; Ren Y; Guo H; Mao R; Xie H; Su H; She Y; Deng J; Yang M; Han B; Zhang Y; Li J; Xie D; Chen C
Ann Transl Med; 2020 Apr; 8(7):470. PubMed ID: 32395514
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
Ko YS; Pyo JS
Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
[No Abstract] [Full Text] [Related]
14. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
[No Abstract] [Full Text] [Related]
15. Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.
Guo C; Zhao H; Wang Y; Bai S; Yang Z; Wei F; Ren X
Front Oncol; 2019; 9():439. PubMed ID: 31192136
[No Abstract] [Full Text] [Related]
16. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
17. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.
Donnem T; Hald SM; Paulsen EE; Richardsen E; Al-Saad S; Kilvaer TK; Brustugun OT; Helland A; Lund-Iversen M; Poehl M; Olsen KE; Ditzel HJ; Hansen O; Al-Shibli K; Kiselev Y; Sandanger TM; Andersen S; Pezzella F; Bremnes RM; Busund LT
Clin Cancer Res; 2015 Jun; 21(11):2635-43. PubMed ID: 25680376
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy.
Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Kinoshita T; Yamada K; Sasada T; Akiba J; Hoshino T
Oncotarget; 2017 Sep; 8(37):61618-61625. PubMed ID: 28977890
[TBL] [Abstract][Full Text] [Related]
19. CD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer.
Paulsen EE; Kilvaer T; Khanehkenari MR; Maurseth RJ; Al-Saad S; Hald SM; Al-Shibli K; Andersen S; Richardsen E; Busund LT; Bremnes R; Donnem T
Neoplasia; 2015 Nov; 17(11):839-48. PubMed ID: 26678911
[TBL] [Abstract][Full Text] [Related]
20. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
